CA3173557A1 - Anti-pd-l1 antibodies and fusion proteins thereof - Google Patents

Anti-pd-l1 antibodies and fusion proteins thereof Download PDF

Info

Publication number
CA3173557A1
CA3173557A1 CA3173557A CA3173557A CA3173557A1 CA 3173557 A1 CA3173557 A1 CA 3173557A1 CA 3173557 A CA3173557 A CA 3173557A CA 3173557 A CA3173557 A CA 3173557A CA 3173557 A1 CA3173557 A1 CA 3173557A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
immunoglobulin
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173557A
Other languages
English (en)
French (fr)
Inventor
Li Peng
Jenny CHE
Lihui Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palleon Pharmaceuticals Inc
Original Assignee
Palleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palleon Pharmaceuticals Inc filed Critical Palleon Pharmaceuticals Inc
Publication of CA3173557A1 publication Critical patent/CA3173557A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3173557A 2021-01-06 2022-01-06 Anti-pd-l1 antibodies and fusion proteins thereof Pending CA3173557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134412P 2021-01-06 2021-01-06
US63/134,412 2021-01-06
PCT/US2022/011504 WO2022150521A1 (en) 2021-01-06 2022-01-06 Anti-pd-l1 antibodies and fusion proteins thereof

Publications (1)

Publication Number Publication Date
CA3173557A1 true CA3173557A1 (en) 2022-07-14

Family

ID=82357548

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173557A Pending CA3173557A1 (en) 2021-01-06 2022-01-06 Anti-pd-l1 antibodies and fusion proteins thereof

Country Status (10)

Country Link
US (1) US20240067729A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274614A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024501771A (cg-RX-API-DMAC7.html)
KR (1) KR20230131236A (cg-RX-API-DMAC7.html)
CN (1) CN116829188A (cg-RX-API-DMAC7.html)
AU (1) AU2022206264A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173557A1 (cg-RX-API-DMAC7.html)
IL (1) IL304190A (cg-RX-API-DMAC7.html)
MX (1) MX2023008028A (cg-RX-API-DMAC7.html)
WO (1) WO2022150521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法
KR20230138473A (ko) * 2021-01-06 2023-10-05 팔레온 파마슈티칼스 인크. 시알리다제-her2-항체 융합 단백질들 및 이의 사용방법
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
EP4744681A1 (en) 2024-08-16 2026-05-20 Shanghai Bao Pharmaceuticals Co., Ltd. COMPLEX TARGETING TARGET CELLS AND ITS USE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170091A1 (en) * 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
KR20150131208A (ko) * 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3277320A4 (en) * 2015-03-30 2018-08-01 Stcube, Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
JP7462560B2 (ja) * 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN111606995B (zh) * 2019-06-04 2021-02-12 优睿赛思(武汉)生物科技有限公司 抗人pd-l1单克隆抗体及其应用
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途

Also Published As

Publication number Publication date
IL304190A (en) 2023-09-01
AU2022206264A1 (en) 2023-07-20
EP4274614A4 (en) 2025-06-18
EP4274614A1 (en) 2023-11-15
US20240067729A1 (en) 2024-02-29
JP2024501771A (ja) 2024-01-15
CN116829188A (zh) 2023-09-29
MX2023008028A (es) 2023-08-14
WO2022150521A1 (en) 2022-07-14
KR20230131236A (ko) 2023-09-12

Similar Documents

Publication Publication Date Title
US20240067729A1 (en) Anti-pd-l1 antibodies and fusion proteins thereof
CA3087529A1 (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
CN114502595A (zh) 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途
CA3145676A1 (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
EP3790586A1 (en) Anti-dll3 antibodies and uses thereof
CA3173145A1 (en) Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same
CA3145747A1 (en) Sialidase-pd-l1-antibody fusion proteins and methods of use thereof
US20240059792A1 (en) Sialidase-her2-antibody fusion proteins and methods of use thereof
CA3145752A1 (en) Sialidase-her2-antibody fusion proteins and methods of use thereof
US20240059773A1 (en) Sialidase-pd-1-antibody fusion proteins and methods of use thereof
CA3145672A1 (en) Sialidase-cd20-antibody fusion proteins and methods of use thereof
EP4671273A1 (en) INTERLEUKIN 21 PROXIMITY ACTIVATED
HK40129808A (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
HK40108974A (en) Anti-btla antibodies and uses thereof in treating cancer
HK40073145A (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
IL314373A (en) ANTI-BTLA antibodies and their use for cancer treatment
HK40073145B (en) Antibodies against the poliovirus receptor (pvr) and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240730

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260217